Correspondence 0001193125-24-179660 from Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc.
Date: July 16, 2024 · CIK: 0001817241 · Accession: 0001193125-24-179660
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280568
Letter
Artiva Biotherapeutics, Inc.
5505 Morehouse Drive, Suite 100
San Diego, CA 92121
July 16, 2024
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Sasha Parikh, Lynn Dicker, Lauren Hamill and Jason Drory
Re: Artiva Biotherapeutics, Inc.
Registration Statement on Form S-1, as amended (File No. 333-280568)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Artiva Biotherapeutics, Inc. (the “Company”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended to date, the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern time, on July 18, 2024, or as soon thereafter as possible, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with Carlos Ramirez of Cooley LLP at (858) 550-6157 or, in his absence, Charles S. Kim of Cooley LLP at (858) 550-6049.
Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.
Very truly yours,
Artiva Biotherapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Artiva Biotherapeutics, Inc. 5505 Morehouse Drive, Suite 100 San Diego, CA 92121 July 16, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Sasha Parikh, Lynn Dicker, Lauren Hamill and Jason Drory Re: Artiva Biotherapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-280568) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Artiva Biotherapeutics, Inc. (the “Company”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended to date, the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern time, on July 18, 2024, or as soon thereafter as possible, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. Once the Registration Statement has been declared effective, please orally confirm that event with Carlos Ramirez of Cooley LLP at (858) 550-6157 or, in his absence, Charles S. Kim of Cooley LLP at (858) 550-6049. Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement. Very truly yours, Artiva Biotherapeutics, Inc. /s/ Fred Aslan, M.D. By: Fred Aslan, M.D. Title: President and Chief Executive Officer cc: Fred Aslan, M.D., President and Chief Executive Officer, Artiva Biotherapeutics, Inc. Jennifer Bush, Chief Operating Officer, Artiva Biotherapeutics, Inc. Neha Krishnamohan, Chief Financial Officer, Artiva Biotherapeutics, Inc. Carlos Ramirez, Cooley LLP Charles S. Kim, Cooley LLP Matthew T. Bush, Latham & Watkins LLP Cheston J. Larson, Latham & Watkins LLP Anthony Gostanian, Latham & Watkins LLP